Alterity Therapeutics (ASXATH) has unveiled a new commercial assessment of its lead candidate ATH434, positioning the therapy as a potential first-in-class treatment for Multiple System Atrophy, a rare and debilitating Parkinsonian disorder with no approved therapies. …
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 Australian Biotech
Latest Video
New Stories
-
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
Taking a stake is not the same as spectating investor risk and expecting a benefit
September 10, 2026 - - Latest News -
Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this
September 10, 2026 - - Latest News -
Melbourne oncologist takes the reins at Australia's private cancer physicians body
September 10, 2026 - -
Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence
September 10, 2026 - - Latest News -
Which is it? The two perspectives on patient input compounded by the lack of transparency
September 10, 2026 - - Latest News